Case Report on Sclerosing Cholangitis

Dr. Shyam Sundar.S1*, Dr. Meena Priya.S1, Dr. B.Santhi2, Dr.Kalai Selvi3, Dr.A.J.Manjula Devi3,
1Tutor, Dept. of Biochemistry, Sree Balaji Medical College and Hospital, Chromepet
2Professor and H.O.D Dept. of Biochemistry, Sree Balaji Medical College and Hospital, Chromepet
3Professor Dept. of Biochemistry, Sree Balaji Medical College and Hospital, Chromepet

*Corresponding author
Dr. Shyam Sundar.S

Article History
Received: 04.09.2017
Accepted: 09.09.2017
Published: 30.09.2017
DOI: 10.21276/sajb.2017.5.9.11

Abstract: Sclerosing cholangitis is a cholestatic liver disease of chronic duration. The main feature of the disease is inflammation and fibrosis of bile duct leading to cirrhosis and final treatment is liver transplantation with less life expectancy. It is most commonly seen in patients with inflammatory bowel disease (IBD). Primary sclerosing cholangitis is of unknown etiology and of immune mediated disease. There are newer techniques like ERCP (Endoscopic Retrograde Cholangiopancreatography) and MRC (Magnetic Resonance Cholangiography) for diagnosing sclerosing cholangitits. There is no proven medical treatment for sclerosing cholangitis. The disease can lead to complications such as dominant strictures, secondary bacterial infection and malignancy mainly cholangiocarcinoma. Liver transplantation is the only therapy recommended for sclerosing cholangitis.

Keywords: Sclerosing Cholangitis, Diagnosis, Therapy, Cholangiocarcinoma, Liver Transplantation

INTRODUCTION
Sclerosing cholangitis is a disease causing inflammation and fibrosis of bile ducts. This leads to obstruction in the flow of bile to intestine and also can lead to cirrhosis of liver [1]. Sclerosing cholangitis is idiopathic and mostly assumed to be auto immune origin, though doesnot respond to immuno suppressants [2]. The sclerosing cholangitis is multifactorial. There are associations between sclerosing cholangitis and human leukocyte antigen (HLA). The levels of serum alkaline phosphatase are increased markedly. Sclerosing cholangitis have auto antibodies and abnormal immunoglobulins. Approximately 80% of people with sclerosing cholangitis have perinuclear Anti-Neutrophil Cytoplasmic Antibodies (ANCA). Antinuclear antibody and anti-smooth muscle antibody are found in 20-50% of patients [4-7]. Sclerosing cholangitis have high associations with inflammatory bowel diseases including ulcerative colitis and Crohn’s disease [3].

CASE REPORT
A 46 years old female came to emergency department with complaints of fever on and off for past one month, pain abdomen for 15 days and vomiting and decreased appetite for past 3 days. Patient also had H/O easily fatigability and generalized itching increased more in past few days. On General examination she was conscious, oriented and co-operative, afibrile. Patient had pallor and icterus and also B/L pedal edema was present. Vitals are normal. On local examination patient had mildly distended abdomen with right hypochondriac tenderness and hepatomegaly. Other systemic examinations were found to be normal. His blood sample was taken and sent for biochemical analysis.

LAB INVESTIGATIONS

CBC
Haemoglobin- 8.9gm% , TLC-26330, N-91% L-3.9% E-0.4%, RBC -3.20 million, MCV- 84.9 fl, MCH-27.28pg, MCHC- 32.8, Platelet – 2.44 lakhs/cu.mm

LFT
Bilirubin (T) and (D): 12.5mg/dl and 10mg/dl, bilirubin indirect: 2.5mg/dl, SGOT: 66IU/L, SGPT: 22IU/L, ALP: 775 IU/L, total protein: 7.3g/dl, albumin: 2.2 g/dl, globulin: 5.1g/dl, A:G ratio: 0.4, Gamma GT(GGT): 192 IU/L

RFT
Urea – 50mg%, Creatinine – 1 mg%

Blood sugar – 110mg%

Serology
ANCA- positive [6].

Urine routine

Proteins, sugar, bile salts and bile pigments: nil
Ascitic fluid tapping:
Total count: 502cells/cu.mm
Sclerosing cholangitis is rare in India. It can be seen in only 4% of patients with IBD. Males are usually more prone for the disease and commonly associated with IBD. Sclerosing cholangitis shows a marked increase in serum autoantibodies levels. ANCA – Anti Neutrophil Cytoplasmic Antibodies are present in 87% of patients with sclerosing cholangitis and anticycadiolipin (aCL) in 66% and antinuclear antibodies (ANA) in 53%. It has increased risk of hepatobiliary malignancy mainly cholangiocarcinoma [13] and life incidence of CCA is 6-23%. ERCP- endoscopic retrograde cholangiopancreatography is successful demonstrating the biliary tree in 95% of cases. Procedure related complications for ERCP occur in 3-8% including abdominal pain, pancreatitis, bleeding, common bile duct perforation, biliary sepsis and death [14,15]. MRC- Magnetic resonance cholangiography has been found more accurate comparable to ERCP [16-20].

DISCUSSION
Sclerosing cholangitis is an immune mediated liver disease associated with morbidity and mortality. There are no proper medical treatments available for sclerosing cholangitis, yet many therapies are yet to be proven. Studies are done for development of therapies and to improve health and halt progress of the disease, thereby decreasing incidence of complications and advanced liver diseases and need for transplantation.

REFERENCES

Available online at http://saspublisher.com/sajb/


